Obizur is a recombinant porcine FVIII treatment. Obizur temporarily replaces the inhibited endogenous factor VIII that is needed for effective hemostasis in patients with acquired hemophilia A.
Obizur is specifically indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.
Obizur is supplied as a powder for solution for intravenous use after reconstitution only.
Submit your review
Adverse effects associated with the use of Obizur may include, but are not limited to. the following:
development of inhibitors to porcine factor VIII.
The recommended initial dose of Obizur is 200 units per kg. The dose and frequency of administration should be titrated based on factor VIII recovery levels and individual clinical response.